Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292


SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

UK Health Watchdog Backs Lung Cancer Drug From Roche

05/09/2012 | 07:16pm US/Eastern

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043;

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
React to this article
Latest news on ASTRAZENECA PLC
01/30 ASTRAZENECA : announces collaborations to use CRISPR technology for genome editi..
01/30DJLONDON MARKETS : FTSE 100 Marks Best Monthly Gain In Nearly A Year
01/30 Three months on, fruitless CEO search overshadows Sanofi
01/30 Ranbaxy loses exclusivity on heartburn drug in us
01/29 ASTRAZENECA : MD Anderson Enter Collaboration to Help Improve Patient Outcomes i..
01/29 Ranbaxy loses US generic exclusivity over $6 bn Nexium
01/29 Ranbaxy loses 180-day exclusivity for generic nexium
01/29 HUTCHISON CHINA MEDITECH : Inks Distribution Deal With AstraZeneca
01/29 ASTRAZENECA : Inks Four Research Collaborations For CRISPR Technique
01/29 AstraZeneca bets on gene editing for broad range of new drugs
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes